Science. Results. Safety.
When one looks at any biologic device or product, one should know that it meets these 3 criteria. Amnion/Amnion- fluid derived biologics, as presented by Anicell Biotech, have cleared these criteria with almost 3,000 cases treated, an efficacy rate over 88%, and a 0% device complication rate.
Historically, Amnion derived treatments, have been around since 1910! A landmark study done by Lange-Consiglio et al, in 2013, showed that equine Amnion-derived therapy (vs equine bone marrow-derived) reduced re-injury rate from 23% to 4%, and reduced the time to return to normal activity by 60%. And in 2017, Larson and Gallicchio in the Journal of Cell Science and Therapy remarked:
- Amnion fluid and it's components are "immune privileged" – meaning it will illicit NO immune response.
- Amniotic Fluid contains many more progenitor cells(pluripotent) than bone marrow (multipotent).
- Amniotic fluid contains hyalorunic acid which aids in joint lubrication and cartilage healing.
- Amniotic fluid contains a full complement of growth factors that promote tissue regeneration.
- Amniotic fluid contains anti-inflammatory and anti-adhesion properties, thereby preventing scar tissue formation
- Amnniotic fluid has anti-infective properties and helps prevent infection from setting in.
- Amnion fluid contains cells that are able to locate damaged areas, and differentiate into many different tissue types (muscle, ligament, tendon, bone, nerve).
Lange-Cosiglio 2013 study on benefits of AMSC (v. BMSC):
Amniotic Derived Stem Cells: Role and Function in Regenerative Medicine(Larson and Gallicchio):